Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results
Strong early U.S. YORVIPATH® launch with 908 prescriptions as of Feb. 7, 2025; YORVIPATH full year 2024 revenue of €28.7 million– Following ...
FiercePharma3h
Inizio Evoke alums flex healthcare marketing prowess with launch of new agency
A group of former leaders from health comms giant Inizio Evoke have come together to launch Flex Marketing, a new agency ...
InterCure Names Alexander Rabinovich as Chairman Replacing Ehud Barak
InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), announces today that Mr. Ehud Barak ...
Oramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral Insulin
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ("Oramed"), a clinical-stage pharmaceutical company focused on the ...
Telix Pharmaceuticals Limited: Illuccix Approved in the United Kingdom
Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United Kingdom (UK) Medicines and Healthcare ...
Illuccix® Approved in the United Kingdom
Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United Kingdom (UK) ...
CATALYX APPOINTS EXECUTIVE CHAIRMAN MARIO L. ROCCI AS CHIEF EXECUTIVE OFFICER
Catalyx, a global leader in machine vision, automation and process control products and services for the life science and consumer goods industries ...
Cytokinetics Names Robert E. Landry To Board Of Directors
Appointment Deepens Financial and Operational Expertise of Boardas Company Approaches Potential Commercialization SOUTH SAN FRANCISCO ...
manilatimes2d
Aquestive Therapeutics to Present New Findings on Anaphylm™ (Epinephrine Sublingual Film) at the 2025 AAAAI Annual Meeting
In the Phase 2 open-label Oral Anaphylm Symptom Intervention Study ("OASIS”) study, adults with Oral Allergy Syndrome (n=36) received Anaphylm under different conditions, including single and repeat ...
Jim Cramer Backs Eli Lilly (LLY): Will Its Drug Pipeline Dominate Pharma?
We recently published a list of Jim Cramer Discusses These 11 Stocks & President Trump’s Sovereign Wealth Fund. In this ...
Business Wire6d
Crown Laboratories Completes Acquisition of Revance Therapeutics
The "Crown" logo, PanOxyl and Blue Lizard are registered trademarks of Crown Laboratories, Inc. SkinPen and StriVectin are registered trademarks of Bellus Medical, LLC and StriVectin Operating Company ...